Literature DB >> 23375264

Cannabis use and cannabis use disorders among individuals with mental illness.

Shaul Lev-Ran1, Bernard Le Foll, Kwame McKenzie, Tony P George, Jürgen Rehm.   

Abstract

BACKGROUND: National epidemiological surveys have reported increased rates of cannabis use and cannabis use disorders (CUDs) among individuals with mental illness. However, this subject has not been sufficiently investigated, particularly given limitations in diagnostic tools used and lack of data pertaining to frequency of cannabis used.
OBJECTIVES: To examine the prevalence of cannabis use and CUDs among individuals with a wide range of mental illness.
METHOD: We analyzed data on 43,070 respondents age 18 and above from the National Epidemiologic Survey on Alcohol and Related Conditions, a nationally representative survey conducted from 2001 to 2002. Main outcome measures included rates of cannabis use by frequency (at least weekly and less than weekly use) and DSM-IV CUDs according to the number and type of axis I and axis II psychiatric diagnoses, assessed by the Alcohol Use Disorders and Associated Disabilities Interview Schedule-IV. We estimated the proportion of cannabis used by individuals with mental illness using reported daily dose and frequency of cannabis used by individuals with and without mental illness.
RESULTS: Rates of weekly cannabis use, less than weekly cannabis use and CUDs among individuals with 12-month mental illness were 4.4%, 5.4% and 4.0%, respectively, compared to 0.6%, 1.1% and 0.4%, respectively, among individuals without any 12-month mental illness (P<0.0001 for all comparisons). The odds ratio for cannabis use among individuals with 12-month mental illness vs. respondents without any mental illness was 2.5, and the odds of having a CUD among individuals with 12-month mental illness were 3.2, after adjusting for sociodemographic variables and additional substance use disorders. Cannabis use and CUDs were particularly associated with bipolar disorder, substance use disorders and specific (anti-social, dependant and histrionic) personality disorders. Persons with a mental illness in the past 12 months represented 72% of all cannabis users and we estimated they consumed 83% of all cannabis consumed by this nationally representative sample.
CONCLUSIONS: The current study provides further evidence of the strong association between cannabis use and a broad range of primary mental illness. This emphasizes the importance of proper screening for frequent cannabis use and CUDs among individuals with primary mental illness and focusing prevention and treatment efforts on this population.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23375264     DOI: 10.1016/j.comppsych.2012.12.021

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  28 in total

Review 1.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

2.  Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada.

Authors:  Didier Jutras-Aswad; Bernard Le Foll; Julie Bruneau; T Cameron Wild; Evan Wood; Benedikt Fischer
Journal:  Can J Psychiatry       Date:  2018-07-22       Impact factor: 4.356

Review 3.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

4.  Sex Differences in the Association Between Cannabis Use and Suicidal Ideation and Attempts, Depression, and Psychological Distress Among Canadians.

Authors:  Jillian E Halladay; Michael H Boyle; Catharine Munn; Susan M Jack; Katholiki Georgiades
Journal:  Can J Psychiatry       Date:  2018-09-27       Impact factor: 4.356

5.  Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential.

Authors:  Sabrina L Botsford; Sharon Yang; Tony P George
Journal:  Am J Addict       Date:  2019-10-02

6.  Potential harms from legalization of recreational cannabis use in Canada.

Authors:  Sarah B Windle; Kristina Wade; Kristian B Filion; Jonathan Kimmelman; Brett D Thombs; Mark J Eisenberg
Journal:  Can J Public Health       Date:  2019-02-13

Review 7.  Pharmacotherapies for cannabis dependence.

Authors:  Kushani Marshall; Linda Gowing; Robert Ali; Bernard Le Foll
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

8.  Negative affectivity as a mechanism underlying perceived distress tolerance and cannabis use problems, barriers to cessation, and self-efficacy for quitting among urban cannabis users.

Authors:  Kara Manning; Daniel J Paulus; Julianna B D Hogan; Julia D Buckner; Samantha G Farris; Michael J Zvolensky
Journal:  Addict Behav       Date:  2017-11-28       Impact factor: 3.913

Review 9.  The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings.

Authors:  Deborah S Hasin; Bridget F Grant
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-07-26       Impact factor: 4.328

10.  Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder.

Authors:  Lauren M Weinstock; Brandon A Gaudiano; Susan J Wenze; Gary Epstein-Lubow; Ivan W Miller
Journal:  Compr Psychiatry       Date:  2015-10-23       Impact factor: 3.735

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.